NEW YORK (GenomeWeb) – Biocept announced today that it has signed an agreement under which its Target Selector liquid biopsy tests and services will be marketed to community-based oncologists and hematologists in the US by Miraca Life Sciences (MLS).

Under the terms of the promotion and marketing deal, Texas-based MLS will promote Target Selector testing to its new and existing clinician clients in certain unnamed sales territories in the US. Biocept will perform the tests at its CLIA lab in San Diego.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.